Literature DB >> 10491144

Cyclosporin A inhibits Ca2+-mediated upregulation of the DNA repair enzyme DNA polymerase beta in human peripheral blood mononuclear cells.

C Ahlers1, S Kreideweiss, A Nordheim, A Rühlmann.   

Abstract

Alterations in gene expression may represent an underlying cause of undesired side-effects mediated by the immunosuppressant cyclosporin A (CsA). We employed the method of differential display PCR to identify new genes whose expression is modulated by CsA. Human peripheral blood mononuclear cells (PBMCs), or subpopulations thereof, were simultaneously stimulated with the phorbol ester 4beta-phorbol 12-myristate 13-acetate (PMA) and the calcium ionophore ionomycin, in the presence or absence of therapeutic concentrations of CsA. We identify the gene encoding the DNA repair enzyme DNA polymerase beta (Pol beta) as a novel CsA-sensitive transcription unit. Our data show that transcription of pol beta mRNA is induced by Ca2+ and that CsA significantly inhibits PMA/ionomycin- and ionomycin-mediated upregulation of both pol beta mRNA and Pol beta protein. The CsA-mediated inhibition of pol beta upregulation is maintained for at least 21 h after gene activation and is exerted via the phosphatase calcineurin. FK506, another immunosuppressant that targets calcineurin, also inhibits pol beta upregulation, while rapamycin competes with FK506 action. This work identifies Ca2+ as an inducer of pol beta gene activity in primary blood cells. The demonstrated CsA sensitivity of this process suggests a novel molecular mechanism that may contribute to the increased tumor incidence in patients receiving CsA treatment.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10491144     DOI: 10.1046/j.1432-1327.1999.00700.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  4 in total

1.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy.

Authors:  Paul D Williams; Charles R Owens; Jaroslaw Dziegielewski; Christopher A Moskaluk; Paul W Read; James M Larner; Michael D Story; William A Brock; Sally A Amundson; Jae K Lee; Dan Theodorescu
Journal:  Neoplasia       Date:  2011-12       Impact factor: 5.715

2.  Cyclosporin-A associated malignancy.

Authors:  Jonathan M Durnian; Rosalind M K Stewart; Richard Tatham; Mark Batterbury; Stephen B Kaye
Journal:  Clin Ophthalmol       Date:  2007-12

Review 3.  Malignancies after lung transplantation.

Authors:  Anne Olland; Pierre-Emmanuel Falcoz; Gilbert Massard
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

4.  Incidental extensive adenocarcinoma in lungs explanted from a transplant recipient with an idiopathic pulmonary fibrosis flare-up: A clinical dilemma.

Authors:  Pradnya D Patil; Samir Sultan; M Frances Hahn; Sreeja Biswas Roy; Mitchell D Ross; Hesham Abdelrazek; Ross M Bremner; Nitika Thawani; Rajat Walia; Tanmay S Panchabhai
Journal:  Respir Med Case Rep       Date:  2018-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.